Abstract: Coumarin-derivative anticoagulant rodenticides used for rodent control are posing a serious risk to wild bird populations. For warfarin, a classic coumarin derivative, chickens have a high median lethal dose (LD50), whereas mammalian species generally have much lower LD50. Large interspecies differences in sensitivity to warfarin are to be expected. The authors previously reported substantial differences in warfarin metabolism among avian species; however, the actual in vivo pharmacokinetics have yet to be elucidated, even in the chicken. In the present study, the authors sought to provide an in-depth characterization of warfarin metabolism in birds using in vivo and in vitro approaches. A kinetic analysis of warfarin metabolism was performed using liver microsomes of 4 avian species, and the metabolic abilities of the chicken and crow were much higher in comparison with those of the mallard and ostrich. Analysis of in vivo metabolites from chickens showed that excretions predominantly consisted of 4′-hydroxywarfarin, which was consistent with the in vitro results. Pharmacokinetic analysis suggested that chickens have an unexpectedly long half-life despite showing high metabolic ability in vitro. The results suggest that the half-life of warfarin in other bird species could be longer than that in the chicken and that warfarin metabolism may not be a critical determinant of species differences with respect to warfarin sensitivity.
the Michaelis constant (K m ) were estimated using Graph Pad Prism 5 (Graph Pad Software).
In vivo analysis: Pharmacokinetics and metabolite composition in fecal samples
Chickens were fasted for 12 h prior to oral administration of warfarin. The administered compound consisted of 3 mg/mL racemic warfarin sodium dissolved in distilled water and was administered at a dose of 1.5 mg/kg body weight. At each sampling time (0 h, 0.5 h, 1 h, 2 h, 3 h, 6 h, 9 h, 12 h, 24 h, and 72 h after oral administration), 200 µL of blood collected via the wing vein was transferred into an Eppendorf tube containing 2 µL heparin. Samples were centrifuged for 30 min at 1000 g within 30 min of collection, and supernatant plasma was collected and stored at −20 °C until extraction.
Warfarin was extracted from plasma using a previously reported method with slight modifications [17] . In brief, 50 µL of plasma were mixed with 10 µL of 7-hydroxycoumarin (10 μg/mL) as an internal standard. After storage for 12 h at 4 °C for equilibration, 190 µL of distilled water containing 0.2% formic acid and 1 mL of acetonitrile containing 0.2% formic acid were added and mixed by vortexing. After incubation at 4 °C for 30 min, the mixture was centrifuged for 15 min at 12 000 g. After the centrifugation, 1 mL of the organic layer was taken and evaporated. Residues were dissolved in 200 µL of the mobile phase used in HPLC analysis. After another centrifugation at 12 000 g for 15 min, an aliquot of 50 µL was taken for further HPLC analysis. Plasma concentrations of warfarin were analyzed by HPLC-UV with the same procedure as used in the warfarin metabolism assay.
Fecal samples were collected in 20 mL of methanol 9 h after administration.
Samples were homogenized and sonicated for 10 min. After centrifugation at 2000 g for 20 min at 4 °C, the supernatant was collected into another tube and another 20 mL of methanol was added to the pellet. The pellet was again homogenized and centrifuged, and the supernatant was collected.
The collected supernatant was hydrolyzed by 10 IU/mL sulfatase and 4000 IU/mL β-glucuronidase and analyzed with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system (Shimadzu).
The metabolite concentration in the samples was calculated using a calibration curve, and the disposition of metabolites was estimated at the 9 h time point.
A Prominence HPLC system (Shimadzu) equipped with an LCMS-8040 (Shimadzu) was used for LC-MS/MS analysis with an electrospray ionization interface.
A TSKgel ODS-120T LC column was used (Tosoh). Mobile phases were water containing 1% acetic acid (A) and acetonitrile containing 1% acetic acid (B). Gradient separation was performed at 10% (B) from 0 min to 2 min, followed by a linear gradient from 10% (B) to 90% (B) from 2 min to 27 min, followed by 10% (B) from 27 min to 30 min. Flow rate was 0.3 mL/min. The ionization mode was negative in the multiple reaction monitoring mode. Collision energies and other optimized MS parameters are shown in Supplemental Data, Table S1 . Nebulizing gas flow was 3 L/min, drying gas flow was 15 L/min, desolvation line temperature was 250 °C, and heat block temperature was 400 °C. Samples and standards were injected at volumes of 10 μL.
Column temperature was maintained at 50 °C. The LOQ was settled as 10 μg/L for each metabolite based on the signal-to-noise ratio. The method was found to be highly accurate, with a relative percentage standard deviation of 1.3% (for 4′-OH) to 4.5% (for 7-OH) within-run precision.
Statistical analysis
Data analyses were performed using the pharmacokinetic software Phoenix WinNonLin (Certara). Pharmacokinetic parameters were estimated with the following conditions: 1 compartment, no lag time, and first-order input and elimination rate.
Statistical analyses were performed based on a Student t test of sex differences in pharmacokinetic parameters of the chicken, and Tukey's honestly significant difference test for species differences in warfarin metabolism using JMP Ver 7.0 (SAS Institute). P < 0.05 was considered significant.
RESULTS

CYP contents in liver microsomes
The CYP contents are shown in Figure 2 . The rank order of average CYP contents was as follows: crow (0.78 ± 0.04 nmol/mg protein) > rat (0.75 ± 0.07 nmol/mg protein) > ostrich (0.42 ± 0.08 nmol/mg protein) > chicken (0.39 ± 0.03 nmol/mg protein) > mallard (0.20 ± 0.01 nmol/mg protein). Crow showed the greatest CYP content and was 3.9 times higher than that of mallard, which had the lowest CYP content. The CYP content in chicken liver microsomes was consistent with previous reports, with values half or less than half of values for rat [18, 19] . Ostrich and mallard also had lower contents than rat. Interestingly, only crow had a similar CYP content to rat. Table 1 shows kinetic parameters for each species and each metabolite. 
Kinetic parameters of in vitro warfarin metabolism in birds
Major metabolites commonly found in bird species
The major metabolite was 4′-OH in all examined bird species. The composition of 4′-OH in the cumulative intrinsic clearance of all metabolites ranged from 66.7% to 94.0%; in comparison, rat had only 30.2%. The K m for 4′-OH was lower in birds than in rat. The lowest K m among metabolites was found for 4′-OH, with the exception of the crow (10-OH).
Pharmacokinetic parameters in chickens
The average plasma concentration of warfarin in chickens is indicated in Figure   4 , with males and females indicated separately. The results of the pharmacokinetic analysis are shown in Table 2 . We observed several sex differences in chickens.
Maximum plasma concentration (C max ) was significantly higher in females. Although the differences in time to maximum concentration (T max ) were not significant, T max was lower in females, half-life (t 1/2 ) was shorter in males, and the area under the curve was lower in males. The t 1/2 in chickens was generally longer than in most mammalian species with the exception of humans (Table 3 ).
In the analysis of warfarin content in plasma, 4′-OH was detected ( Figure 5 ).
The shape of 4′-OH implies the possibility of hepatic-intestinal circulation. The clearance of 4′-OH was found to be slower than that of warfarin.
Metabolite composition in in vivo excretions
Metabolite compositions including unmetabolized warfarin found in the fecal samples are indicated in Figure 6 . Unmetabolized warfarin accounted for approximately 20% and 40% of all excreted warfarin-related compounds in male and female chickens, respectively. Other than warfarin, 4′-OH and 6-OH were prevalent; whereas 7-OH was identified only in excretions of female chickens. The metabolites 4′-OH and 6-OH accounted for 87.2% and 12.8% of the 5 metabolites in male chickens and for 84.0% and 11.1% in female chickens, respectively.
DISCUSSION
Species difference in in vitro warfarin metabolic activity
We previously reported a large interspecies difference in warfarin metabolic activity based on a single high substrate concentration of 400 µM [14] . However, the actual concentration of warfarin in vivo is lower. For example, the C max of a female dosed with 1.5 mg/kg body weight at 4.5 µg/mL is approximately 15 µM. In the present study, we performed a kinetic analysis of warfarin metabolism to determine enzymatic efficiency, which reflects the warfarin metabolic ability at very low concentrations. The results showed that chicken and crow had higher enzymatic efficiency than other birds and that the enzymatic efficiency of crow was 11-fold higher than that of mallard.
Because crow with the highest enzymatic efficiency also showed the highest CYP contents used as a normalizer, we suggest that the species difference in warfarin metabolic ability in vivo may be even larger than the species difference in the enzymatic efficiency determined in the present study.
4′-OH as a common major metabolite in bird species
Based on the kinetic analysis, the common dominant metabolite in the examined bird species was 4′-OH. In humans, 4′-OH is commonly produced by CYP2C8, CYP2C9, CYP2C18, and CYP2C19, in contrast to CYP2B1 and CYP2C11 in rats [10, 20] . In chickens, we previously showed the dominance of CYP2C genes in a comparative mRNA study of chicken liver and suggested that CYP2Cs are the dominant enzymes in the xenobiotic metabolism in the chicken [21] . No CYP2B genes for these bird species could be found in GenBank. We therefore may speculate that avian CYP2C isoforms are a major contributor to 4′-hydroxylation of warfarin.
In guinea pigs 4′-OH not only inhibits human CYP2C9 but also shows anticoagulant activity [22, 23] . Further investigation is needed to clarify the characteristics specific to avian species in terms of in vivo pharmacokinetics of warfarin and 4′-OH, as well as the CYP-mediated 4′-hydroxylation in birds.
In vivo analysis in parallel to in vitro analysis
The rank order of enzymatic efficiency in vitro for each metabolite in chicken was 4′-OH > 6-OH > 7-OH > 8-OH > 10-OH. The ranking of prevalence of in vivo metabolites in assessed excretions showed that 4′-OH is the dominant metabolite, followed by 6-OH and 7-OH, the latter of which was observed only in female chickens.
In contrast, in vitro metabolism produced 8-OH and 10-OH, which were not detected in in vivo excretions. This discrepancy can be explained by the high K m of the 8-OH and 10-OH pathways in vitro as the in vivo warfarin concentrations were much lower.
Moreover, the major metabolite in chicken (4′-OH) was the only metabolite observed in plasma after oral administration of warfarin. The results from the in vitro and in vivo assays were consistent in terms of metabolite patterns and relative quantity.
We therefore were able to confirm that in vitro warfarin metabolism in liver tissue of the 4 avian species studied is consistent with in vivo warfarin metabolism in chickens.
Sex difference in chicken warfarin metabolism in vivo
The sex difference in warfarin pharmacokinetics suggested rapid absorption in female chickens and rapid metabolism and elimination in male chickens. The CYP contents and activity, as indicated by ethoxy-resorufin-O-deethylase, coumarin 7-hydroxylase, hexobarbital hydroxylase, and ethoxy-coumarin deethylase, were higher in male chickens [24] . This may suggest that warfarin metabolic ability is greater in male chickens.
A similar case was also observed in rats. Significant sex differences were observed in area under the curve and terminal half-life [25] . This was likely because of sex differences in CYP isoforms as CYP2C11 and CYP3A2 are male-specific and CYP2B1 is also dominant in male rats.
CYP as a determinant of sensitivity in birds
The LD50 of warfarin in chicken is reported to be 942 mg/kg, suggesting that it is unlikely that chicken would die from warfarin ingestion at environmentally realistic concentrations [26] . We previously clarified the resistance mechanism with respect to 2 aspects: CYP enzymes mediating warfarin metabolism and the target enzyme of warfarin, vitamin K epoxide reductase [14] . That study presented both "high warfarin metabolic ability" (~60-fold that of owls) and a "low inhibitory effect of warfarin on chicken vitamin K epoxide reductase activity." However, no study has compared in vivo pharmacokinetics between birds and mammals.
A pharmacokinetic analysis of the chicken was performed in the present study, with the expectation that warfarin might display a shorter half-life in chicken than in rat (Table 3) . Surprisingly, the half-life of warfarin in chicken was longer than in most mammalian species despite the high warfarin metabolic ability in vitro. In humans, a very large proportion of warfarin in plasma is bound to albumin (~99%), in contrast to rats, where albumin has only 1 warfarin-binding site [27, 28] . Free warfarin can be subject to CYP metabolism and renal excretion; thus, the low amount of free warfarin with respect to warfarin binding to albumin can result in a longer half-life in chickens. This is analogous in terms of warfarin toxicity. Free warfarin can inhibit the target enzyme, vitamin K epoxide reductase. This suggests that chicken albumin may have a greater warfarin-binding capacity, resulting in a longer half-life and less toxicity despite high metabolic ability, although the albumin concentration of the birds including chicken is generally lower (0.2-2.4 g/dL) than that of mammals (normal concentration in human is 4-5 g/dL) [29, 30] . In contrast to this, the tissue half-life of another anticoagulant, diphacinone, in American kestrel is shorter than that of rat. Further study is needed to clarify the pharmacokinetic difference of free warfarin and protein-bound warfarin separately in other birds as well as the difference of pharmacokinetics among the anticoagulant rodenticides in birds.
CONCLUSION
Although warfarin is readily metabolized by birds, it was found that the half-life of warfarin in chickens is relatively long in comparison with other mammalian species. Other bird species may have much longer warfarin half-lives, with the implication that a single dose could be sufficient to cause toxicity, depending on the inhibition rate constant of vitamin K epoxide reductase. Further study is needed to clarify in vivo warfarin pharmacokinetics and detailed albumin binding of warfarin in avian species. K10_HL = plasma half-life; CL_F = oral clearance; T max = time to maximum concentration; C max = maximum concentration; SD = standard deviation. Eason et al. [37] Cat
